Sublingual buprenorphine for acute renal colic pain management: a double-blind, randomized controlled trial by Pooya Payandemehr et al.
Payandemehr et al. International Journal of Emergency Medicine 2014, 7:1
http://www.intjem.com/content/7/1/1ORIGINAL RESEARCH Open AccessSublingual buprenorphine for acute renal colic
pain management: a double-blind, randomized
controlled trial
Pooya Payandemehr1, Mohammad Jalili1*, Babak Mostafazadeh Davani2 and Ahmad Reza Dehpour3Abstract
Background: The aim of this study was to compare the efficacy and safety of sublingual buprenorphine with
intravenous morphine sulfate for acute renal colic in the emergency department.
Methods: In this double-dummy, randomized controlled trial, we enrolled patients aged 18 to 55 years who had a
clinical diagnosis of acute renal colic. Patients received either 2 mg sublingual buprenorphine with an IV placebo,
or 0.1 mg/kg IV morphine sulfate with a sublingual placebo. Subjects graded their pain with a standard 11-point
numeric rating scale (NRS) before medication administration and 20 and 40 minutes after that. The need for rescue
analgesia and occurrence of side effects were also recorded in the two groups.
Results: Of 69 patients analyzed, 37 had received buprenorphine, and 32 had taken morphine. Baseline characteristics
were similar in both groups. NRS pain scores were reduced across time by administration of both buprenorphine (from
9.8 to 5.22 and then 2.30) and morphine (from 9.78 to 4.25 and then 1.8), significantly (P <0.0001). The two regimens did
not differ significantly for pain reduction (P = 0.260). Dizziness was more frequently reported by the buprenorphine group
(62.1% versus 37.5%, P <0.05) but other adverse effects observed within 40 minutes were similar in the two groups.
Conclusions: Sublingual buprenorphine (2 mg) is as effective as morphine sulfate (0.1 mg/kg) in acute renal colic pain
management.
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Renal colic is a severely painful condition frequently
encountered in emergency departments (EDs) [1]. As
relieving the patient’s pain and suffering is one of the first
responsibilities of emergency physicians, finding safe and
effective methods to accomplish this task is of paramount
importance [2]. The routine practice for pain reduction in
renal colic is intravenous (IV) administration of analgesics,
either non-steroidal anti-inflammatory drugs or opioids
[3]. IV administration of these drugs, although effective,
takes a lot of staff time, which is not ideal in constantly
overcrowded EDs. On the other hand, ‘time to analgesia’ is
an indicator of ED service quality, which will be much
longer when using a parenteral route for analgesia [4]. The
ideal analgesic drug is one with enough efficacy and the
fewest side effects as well as easy route of administration.* Correspondence: mjalili@tums.ac.ir
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reproduction in any medium, provided the origBuprenorphine is an analgesic with mixed agonist-
antagonist properties which has been shown to have a
role in acute pain management in postoperative pain
and orthopedic injuries [5,6]. However, there is only one
study evaluating its effectiveness in renal colic [7] and,
to the best of our knowledge, there is no study using the
sublingual form of buprenorphine as an analgesic in
renal colic. Its sublingual form can be administered
rapidly and with no need for IV lines, and hence may be
an ideal drug for acute pain management in renal colic.
We compared the effectiveness of sublingual bupre-
norphine with that of IV morphine sulfate for pain
management in ED patients with renal colic.
Methods
Study design
This is a double-dummy, placebo controlled randomized
clinical trial in patients with acute renal colic in the ED.
Using block randomization (with a computer generated
sequence) and a sealed envelope mechanism for allocationThis is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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receiving sublingual buprenorphine with IV placebo and
the other receiving IV morphine with sublingual placebo.
The study was performed in the emergency department of
Imam Hospital, a tertiary referral center with appro-
ximately 50,000 visits per year. The ethics committee
approved the study protocol and the study was registered
in www.clinicaltrials.gov (NCT01546701).
Study setting and population
Eligible patients for our study were those with acute
colicky pain aged between 18 and 55 years old and who
had a clinical diagnosis of acute renal colic based on
medical history and a positive urinalysis for hematuria.
The numerical rating scale (NRS), validated by Bijur
et al., was used to measure severity of pain [8]. All
patients with a pain score of more than 3 who signed
the informed consent, were enrolled in the study. We
excluded patients with previous history of seizure;
cardiovascular, hepatic, renal or metabolic diseases;
febrile patients (T >38°C); hemodynamically unstable
patients (systolic blood pressure <90 mmHg); and preg-
nant patients. We also excluded patients with abdominal
tenderness as a sign of peritoneal inflammation and
those with any clinical suspicion for diseases other than
urolithiasis, including abdominal aortic aneurysm or
dissection. Patients with a history of drug addiction or
known allergy to opioids and those who had received
analgesics 6 hours before arriving at the ED were also
excluded to prevent any possible drug reactions.
Study protocol
Eligible patients were randomly allocated into two
groups to receive either sublingual buprenorphine as 2
mg tablets plus IV injection of 0.1 mL/kg sterile water
or a sublingual placebo plus 0.1 mg/kg IV morphine
sulfate (1 mg/mL). All the researchers and participants
remained blind to the treatment and results throughout
the study.
Outcome measures
The primary outcome was the efficacy of the drug with
regards to reducing the NRS 20 and 40 minutes after
administration and the need for rescue analgesia, which
was an IV injection of fentanyl (0.75 μg/kg). The secondary
outcome was the occurrence of adverse effects.
Measurements
Patients were asked to rate their pain in a verbally
administered NRS with 0 representing no pain and 10
the worst imaginable pain. The severity of pain was ree-
valuated at 20 and 40 minutes after analgesic administra-
tion. The patients were monitored for any change in
their vital signs including blood pressure, pulse rate,respiratory rate and oxygen saturation during the study.
Hypotension was defined as a drop of more than 20
mmHg in systolic blood pressure, and respiratory
depression as a respiratory rate below 12 (if it was
initially more than 12 per minute). The patients were also
asked about their feelings of nausea, vomiting, dizziness,
pruritus, or drowsiness.
Data analysis
Baseline demographic and clinical variables were com-
pared using independent Student’s t-tests or exact tests.
Repeated measure ANOVA was used to assess the effect
of intervention on pain scores across time and between
the study groups at each time point. Side effects were
compared using χ2 tests and P <0.05 was considered
statistically significant. The sample size was calculated as
25 for each group according to the study conducted by
Finlay et al. [7] with α and β error being 0.05 and 0.20,
respectively. We enrolled 80 patients to cover possible
withdrawals from the study. All analyses were performed
using the Statistical Package for Social Science version
15 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Between March 2011 and April 2012, 118 patients with
acute renal colic were assessed for eligibility, 38 were
excluded from randomization because they did not meet
the inclusion criteria and 80 were enrolled and rando-
mized into the two treatment groups. During the study
period, 11 patients were lost to follow-up. Of 69 patients
whose data were finally analyzed, 37 and 32 received
buprenorphine and morphine, respectively (Figure 1).
Baseline characteristics were similar in the two groups
(Table 1).
Primary outcome
There was no significant difference between NRS scores
of the two study groups at the beginning of the study.
The NRS pain scores showed a significant reduction
across time (P <0.001) when analyzed using the repeated
measure ANOVA in both groups (Table 2). The two
groups did not differ significantly for pain reduction
(P = 0.260) (Figure 2). The use of rescue analgesia was
not significantly different in the two groups (Table 2).
Secondary outcome
There was also no significant difference between the
study groups regarding patients’ vital signs after admi-
nistration of the medications except for the respiratory
rate 20 minutes after treatment, which was significantly
lower in the morphine group (mean 11.41 bpm vs. 12.27
bpm) (P = 0.017). No significant difference between the
two groups was noted in terms of respiratory depression
Figure 1 Flow of participants through trial.
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between the two groups regarding the occurrence of
nausea, vomiting or pruritus, except that the patients in
buprenorphine group reported dizziness more frequently
(P <0.05) (Table 3). There were no cases of seizure or
loss of consciousness in either group.Table 1 Baseline demographic and clinical characteristics
of study participants
Group Buprenorphine n = 37 Morphine n = 32
Female (%) 9.84 (±0.50) 9.78 (±0.55)
Mean age (year)* 35 (±10) 31 (±10)
Respiratory rate (per minute)* 13.38 (±1.55) 13.13 (±1.28)
Pulse rate (per minute)* 90.95 (±9.40) 94.63 (±11.48)
*Values in mean (±SD).Discussion
The results of this study demonstrated that adminis-
tration of 2 mg sublingual buprenorphine effectively
reduced pain in patients with acute renal colic. Although
the number of patients was not enough to perform
equivalency tests, the results showed that the analgesic
effect of buprenorphine was comparable to 0.1 mg/kg IV
morphine.Table 2 Pain scores in study groups
Group NRS0* NRS20* NRS40* Rescue analgesia**
Buprenorphine 9.84 (±0.50) 5.22 (±2.66) 2.30 (±2.09) 5 (13.5%)
Morphine 9.78 (±0.55) 4.25 (±2.51) 1.78 (±2.45) 2 (6.25%)
*Mean numerical rating score (±SD) at baseline and after 20 and 40 minutes.
**Number of patients who needed rescue analgesia after 40 minutes.
Figure 2 NSR pain score over the study period.
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on sublingual buprenorphine in the treatment of renal
colic in the ED. However, our results are compatible with
the results of a previous study in this center on the ef-
fectiveness of sublingual buprenorphine in acute bone
fractures [6]. In that study, patients with acute extremity
fractures received either sublingual buprenorphine (0.4 mg)
or IV morphine (5 mg). The pain scores were compared
after 30 and 60 minutes and there was no significant diffe-
rence between the two groups [6]. Our results are also
comparable with the results of Risbo et al. [9] and Abid
et al. [10], who studied buprenorphine in post-operative
pain management. In the first study, buprenorphine was
compared with intramuscular morphine as an analgesic for
pain management after elective knee joint surgery, where
they demonstrated similar efficacy [9]. In the second study,
Abid et al. found buprenorphine as effective as morphine
for post-operative pain management in patients undergoing
a Caesarean section [10]. Furthermore, according to the
findings of this study, patients in the buprenorphine groupTable 3 Occurrence of side effects in the study groups
Group Nausea Vomiting Drowsiness Pru
Buprenorphine 20 (54%) 4 (10.8%) 6 (16.2%) 0 (
Morphine 20 (62.5%) 3 (9.3%) 6 (18.7%) 1 (3
P value† 0.47 1.000 0.782 0.
*Statistically significant (P <0.05).
†χ2 test, Fisher’s exact test.reported dizziness more frequently but other adverse effects
observed within 40 minutes were similar in the two groups.
Walsh et al. [11] showed that increasing buprenorphine
dose will increase its analgesic effect but not its side effects.
Comparing to the results of a study in which lower dose of
buprenorphine was used (0.4 mg) and no adverse effect
was reported [6], it seems that higher doses will increase
analgesic efficacy without affecting the side effects.
Limitations
Our study faced several limitations. First, many patients
had to be excluded due to previous use of opioids or
addiction. Secondly, some of the patients might have
been drug seekers and IV drug users imitating renal
colic to get morphine. It is possible that they were not
recognized and were included in study. Thirdly, NRS
may be an inappropriate measurement upon arrival of
the patients as they tend to choose the highest NRS
(i.e., 10), assuming that this will accelerate their treat-
ment process. It may justify the number of patientsritus Dizziness Respiratory depression Hypotension
0%) 23 (62.1%)* 10 (27%) 17 (45.9%)
.1%) 12 (37.5%) 11 (34.3%) 15 (46.8%)
464 0.041 0.508 0.938
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tion is expected to be similar in both groups and does
not seem to influence the change in NRS during the
observation time. Another limitation of our study was
the use of 2 mg buprenorphine tablets which may be the
cause of slightly higher rate of side effects in this group;
using smaller doses and then titrating it to effect may
reduce the occurrence of side effects. Finally, this study
did not find a significant difference between the two
groups probably because of the small sample size.
Conclusions
In conclusion, sublingual buprenorphine can be used as
an effective analgesic with minor side effects for acute
pain relief in patients with renal colic, and its effective-
ness is comparable to that of IV morphine.
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